Prestige Brands recall: CLEAR EYES Maximum Itchy Eye Relief
Prestige Brands Holdings is recalling CLEAR EYES Maximum Itchy Eye Relief because of a sterility problem – 39,060 15mL-bottles. The U.S. Food and Drug Administration published the recall on August 19, 2026; it began on July 29, 2026. Distributed nationwide.
Serious Class II means the product may cause temporary or medically reversible health problems, or the chance of serious harm is remote.
Share
| Product | CLEAR EYES Maximum Itchy Eye Relief |
| Brand | Prestige Brands |
| Company | Prestige Brands Holdings |
| Type | Drugs |
| Classification | Class II |
| Recall date | July 29, 2026 |
| Published by FDA | August 19, 2026 |
| Quantity | 39,060 15mL-bottles |
| Recall ID | 99532 |
Recalled products
- CLEAR EYES Maximum Itchy Eye Relief, 0.5 fl oz (15 mL) per dropper bottle, Sterile, Dist. by Medtech Products Inc., Tarrytown, NY 10591, a Prestige Consumer Healthcare Company. NDC: 67172-999-01 UPC 6 78112 65920 3
- FDA recall number
- D-0766-2026
- Codes, lots and dates
- Lot 2552A, Exp 09/30/2027
- Quantity
- 39,060 15mL-bottles
- Classification
- Class II
Identifiers and details
- FDA event ID
- 99532
- Initiated
- Voluntary: Firm initiated
- Status
- Ongoing
- Firm location
- Tarrytown, NY, United States
Why it was recalled
The problem: a sterility problem.
The reason the FDA lists: “Lack of assurance of sterility. The recall is due to potential contamination”
Where it was sold
Nationwide. Distribution as the FDA records it: “Nationwide in the USA.”
What to do
Compare the recall numbers, lot numbers and expiration dates with what you have. Do not stop a prescribed medicine or device without talking to your pharmacist or doctor – they can arrange a replacement from an unaffected lot.
Official notice: FDA Enforcement Report record (event 99532, openFDA) – the same recall numbers can be searched in the FDA Enforcement Report.
Other drug recalls
| Date | Recall | Problem | Agency |
|---|---|---|---|
| Oct 7, 2026 |  Ajanta Pharma recall: Ranolazine Extended-Release TabletsDrugs | Failed Dissolution Specifications: below specification Serious | FDA Class II |
| Oct 7, 2026 | Par Health recall: Buprenorphine HydrochlorideDrugs · 154210 bottles | Crystallization Serious | FDA Class II |
| Oct 7, 2026 | Apotex recall: Paroxetine Extended-Release TabletsDrugs | Failed dissolution specifications. Serious | FDA Class II |
| Oct 7, 2026 | TerSera Therapeutics recall: ZoladexDrugs · 296 cartons | Temperature Abuse: Product sat in a non-temperature-controlled FedEx trailer at ambient ou… Serious | FDA Class II |
| Oct 7, 2026 | Aurolab Trust recall: FOCUS PI Hypromellose 0.7% FormulaDrugs · 25,220 bottles | a sterility problem Serious | FDA Class II |
| Oct 7, 2026 | Amneal Pharmaceuticals recall: Estradiol GelDrugs · 2,592 30-count cartons | Defective Container; packets were found to be either empty or partially full. Serious | FDA Class II |
About this recall
Is Prestige Brands CLEAR EYES Maximum Itchy Eye Relief recalled?
Yes. Prestige Brands Holdings recalled it on July 29, 2026; FDA published it August 19, 2026 (Class II). Only the lots, dates or models listed on this page are included.
Why was it recalled?
Because of a sterility problem. The reason given: Lack of assurance of sterility. The recall is due to potential contamination
What should I do if I have it?
Compare the recall numbers, lot numbers and expiration dates with what you have. Do not stop a prescribed medicine or device without talking to your pharmacist or doctor – they can arrange a replacement from an unaffected lot.
Where was it sold?
Nationwide.
More recalls
Source: recall records published by the U.S. Food and Drug Administration (openFDA Enforcement Reports), the USDA Food Safety and Inspection Service, the Consumer Product Safety Commission and the National Highway Traffic Safety Administration, collected twice a day. Product names, lot codes, dates and model numbers are shown exactly as the agency lists them; the agency's notice is the authority. 77.today is not affiliated with any of these agencies.